Spots Global Cancer Trial Database for Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation

Official Title: A Single Center, Open Label, Dose-Finding Study to Determine the Safety of Icotinib in Combination With Whole Brain Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation.

Study ID: NCT01516983

Conditions

Non-small Cell Lung Cancer

Brain Metastases

Interventions

icotinib

Whole brain radiotherapy

Study Description

Brief Summary: The purpose of this study is to evaluate the safety and tolerability of Icotinib at different dose levels in combination with whole brain radiotherapy for NSCLC patients with brain metastases and EGFR mutation.

Detailed Description: The long-term control of brain metastases becomes a clinical challenge. Whole brain radiotherapy, the standard treatment for patients with multiple brain metastases, can only bring a modest survival improvement around 3-6 months. EGFR-TKIs like icotinib with its proven activity in non-small cell lung cancer may provide clinical benefits in such patients.